Mallinckrodt Inc. Announces Approval of New Gablofen® Prefilled Syringe

Published: Jan 22, 2013

HAZELWOOD, Mo.--(BUSINESS WIRE)--Mallinckrodt, the Pharmaceuticals business of Covidien (NYSE: COV), today announced the U.S. Food and Drug Administration (FDA) approval of Gablofen® (baclofen injection) in prefilled syringes. The Gablofen prefilled syringe was created to reduce preparation steps, helping to simplify the pump refill process for patients receiving ITB TherapySM (Intrathecal Baclofen Therapy) to treat severe spasticity of cerebral and spinal origin. “The launch of Gablofen prefilled syringe enhances our product portfolio and provides a known treatment in a convenient delivery technology,” said Mark Trudeau, President, Mallinckrodt. “The prefilled syringe has the opportunity to replace the traditional glass ampules and simplify the pump refill process for healthcare providers treating appropriate patients with severe spasticity.”

Back to news